Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will issue its interim results for the six month period ended 31 December 2015 on Tuesday 8(th) March 2016.
A meeting for analysts will be held at 9:30am at the offices of Panmure Gordon at 1 New Change, London, EC4M 9AF. Manuel Llobet, Chief Executive Officer, and Ian Postlethwaite, Chief Financial Officer, will provide an update on the Company with a Q&A session which will be accessible remotely via a live conference call. The details of the call will be provided in the statement on Tuesday 8(th) March.